News | August 04, 2021
NATCO Pharma transfers Lenalidomide ANDA to Arrow
Arrow is the marketing partner in US
Arrow is the marketing partner in US
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
Subscribe To Our Newsletter & Stay Updated
